Who are L19IL2 + L19TNF's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FAP IL2V.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/l19il2-l19tnf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

L19IL2 + L19TNF — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

L19IL2 + L19TNF (L19IL2 + L19TNF) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody-cytokine fusion. Area: Oncology.

phase 3 Bispecific antibody-cytokine fusion Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

L19IL2 + L19TNF (L19IL2 + L19TNF) — Philogen S.p.A.. L19IL2 + L19TNF is a bispecific antibody-cytokine fusion combination that targets tumor vasculature via the L19 antibody while delivering IL-2 and TNF directly to the tumor microenvironment.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L19IL2 + L19TNF TARGET	L19IL2 + L19TNF	Philogen S.p.A.	phase 3	Bispecific antibody-cytokine fusion	Fibronectin extra domain B (EDB); IL-2 receptor; TNF receptor
FAP IL2V	FAP IL2V	Hoffmann-La Roche	phase 3	Bispecific antibody-cytokine fusion	FAP (fibroblast activation protein) and IL-2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody-cytokine fusion class)

Hoffmann-La Roche · 1 drug in this class
Philogen S.p.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). L19IL2 + L19TNF — Competitive Intelligence Brief. https://druglandscape.com/ci/l19il2-l19tnf. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab